What is the official account of WeChat Zhengzhou vaccine reservation?

COVID-19 vaccine in Zhengzhou is not open to the public for appointment.

At the "2002110 press conference on epidemic prevention and control in COVID-19 in winter and spring in Zhengzhou", Duan, deputy commander of the vaccine special class of Zhengzhou epidemic prevention and control headquarters and deputy director of Zhengzhou Health and Health Commission, said that the key groups that are given priority for vaccination at present mainly include imported cold-chain food, port quarantine, aircrew and large-scale farmers.

Duan said that China's current vaccination strategy is to follow the "two-step" plan, and the first step is to vaccinate key populations. In the second step, after the vaccine is approved, the eligible public can meet the requirements through orderly vaccination.

Extended data

Key population for emergency vaccination in COVID-19, Zhengzhou;

A: This emergency vaccination is mainly aimed at key personnel with high risk of contracting COVID-19 virus.

Frontier customs inspection and quarantine personnel involved in the import of cold chain goods, port loading and unloading, handling, transportation and other related personnel, international and domestic transportation practitioners, overseas work-study program personnel, border port staff facing high risk of overseas epidemic, medical and health personnel, government agencies, public security, armed police, fire fighting, community workers, water, electricity, gas and other related personnel, transportation, logistics, pension, health, funeral.

When can Zhengzhou ordinary citizens start vaccination? According to the introduction of the the State Council Joint Prevention and Control Mechanism Meeting, after the COVID-19 epidemic, China laid out five technical routes to promote vaccine research and development. By 2020, 65438+February 29th, according to the statistics of the World Health Organization, our vaccines entering clinical trials and those entering phase III clinical trials are in the first phalanx in the world.

Because the epidemic situation was controlled earlier in China, and the conditions for conducting phase III clinical trials were not available in China, the five vaccines that entered the phase III clinical trials in China were all phase III clinical trials conducted abroad. After the data is uncovered, the relevant data will be announced to the public in time. If the data meet the corresponding standards, National Medical Products Administration will approve the conditional listing or listing.

By then, the general public can be vaccinated according to the relevant national policies and vaccine supply.

China News Network-Zhengzhou Chao 1 1 10,000 people vaccinated with COVID-19 vaccine will cover high-risk posts.